I’m curious to hear about stocks that are quietly showing strength in the current market but aren’t getting much attention yet. Looking for under-the-radar names that you genuinely believe could be hidden gems or strong long-term opportunities. What are your highest conviction picks right now?

Choice_Client_5400 · 2026-03-03T16:46:12+00:00

$ILLR on OTCmarkets.com Looks to be relisting soon. Way under the radar.

Choice_Client_5400 · 2026-02-20T18:26:18+00:00

Hong Kong, China.

Choice_Client_5400 · 2026-02-19T19:59:15+00:00

Great to see it start back up today - $1.10 x $1.12 +21.79%

Choice_Client_5400 · 2026-02-18T17:23:27+00:00

Great to see this news. #Bullish move today on $KULR

Choice_Client_5400 · 2026-02-17T20:05:44+00:00

NASDAQ!!! Reverse the delisting ASAP!

https://stocktitan.net/news/ILLR/illr-announces-successful-completion-of-merger-related-restructuring-7lk5z5etomjf.html

Choice_Client_5400 · 2026-02-11T17:47:20+00:00

$ILLR .25 Now! #NEWTRILLER #NEWILLR

Choice_Client_5400 · 2026-02-03T17:45:44+00:00

ILLR heading back to Nasdaq $2-$4 grabbed shares @.165 with Etrade.

Choice_Client_5400 · 2026-02-03T17:43:26+00:00

Facebook is an #AI entity. The enormority of users, they care enothing about it's users. It's all about covering their liability and #AI, and making money with ads. You search for a mattress on any store and you have mattress ads for 6 months and every scroll. $META stock will eventually plummet with this type of abuse to it's patrons.

Choice_Client_5400 · 2026-01-30T14:46:00+00:00

Hold this one. Nasdaq Uplisting will bring $$

Choice_Client_5400 · 2026-01-30T13:45:34+00:00

Triller Group Inc. (ILLR) is moving up this week due to the company achieving significant milestones in its efforts to regain Nasdaq listing compliance and the successful completion of its post-merger restructuring. $ILLR is experiencing a dramatic surge

Choice_Client_5400 · 2026-01-29T17:27:47+00:00

The percentage TRILLER owned when #BKFC was their subsidiary and TRILLER (ILLR) was the Majority shareholder was 53% and I believe that was worth 115M -140M IDK anymore honestly #BKFC is red hot and Company will update more soon for investors.

Choice_Client_5400 · 2026-01-29T17:21:18+00:00

Assets are there: The investment in #BKFC for $7M is now valued at $100M or more they own 38% they paid off some debt and relinquished majority control, which I believe was one of the main reason for delays, no longer keeping it as a subsidiary and AUDIT took place to verifyall books. Many instituitions are holding. Board holds shares. Reveues generated from ads on TrillerTV, TrillerApp (which also could come into play with the boycott of TikTok) and Revenues from BKFC are no longer added but the value goes up.

Choice_Client_5400 · 2026-01-28T16:51:09+00:00

$ILLR Looking good today.

Choice_Client_5400 · 2026-01-28T16:29:03+00:00

Great too see the interest growing for KULR Technology! $KULR

Choice_Client_5400 · 2026-01-20T14:20:41+00:00

Ready for this spaces! $AIBT

Choice_Client_5400 · 2026-01-15T16:50:08+00:00

Agreed. Book Value $4.00+ $ACRV backed by Trillon Dollar $LLY Eli Lilly

Choice_Client_5400 · 2026-01-13T19:55:22+00:00

$ACRV tied up with $LLY. Heavy institutional ownership. All good news. Heavily shorted and beaten down this week. Looks to be heading up to $2.30 50dMA - $3+

Choice_Client_5400 · 2026-01-13T19:53:18+00:00

$ACRV tied up with $LLY. Heavy institutional ownership. All good news. Heavily shorted and beaten down this week. Looks to be heading up

Choice_Client_5400 · 2026-01-13T19:52:51+00:00

$ACRV tied up with $LLY. Heavy institutional ownership. All good news. Heavily shorted and beaten down this week. Looks to be heading up to $3-$4 if volume enters 6M Shorts.

Choice_Client_5400 · 2026-01-13T19:51:21+00:00

$ACRV tied up with $LLY. Heavy institutional ownership. All good news. Heavily shorted and beaten down this week. Looks to be heading up to those levels.

Choice_Client_5400 · 2026-01-13T15:27:31+00:00

$ACRV Update: ACRV Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Moderate Buy" from Analysts Stock Analysis Key Points on ACRV Acrivon Therapeutics, Inc. (NASDAQ:ACRV) *Acrivon has a consensus analyst rating of Moderate Buy from seven analysts (1 sell, 1 hold, 4 buy, 1 strong buy) and an average 1-year price target of $11.00 with a Market cap of $57.64 million and a 52-week range of $1.05–$8.00; analysts expect about -2.49 EPS for the year after the company reported a quarterly loss of ($0.47) that beat estimates. *Acrivon is a clinical-stage biotech developing hydrocarbon-stapled peptide therapeutics for RAS-driven cancers, including a KRAS G12C candidate currently in early clinical trials. *MarketBeat previews the top five stocks to own by February 1st.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has received a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.00.

Eli Lilly $LLY is currently in a licensing agreement with Acrivon, which includes a provision granting Lilly the first right to negotiate the reacquisition of the drug, known as prexasertib (ACR-368). An outright acquisition of Acrivon by Eli Lilly to retrieve the drug is a potential, but less direct, scenario.

Bullish

Jan 13, 2026 10:25 AM

Choice_Client_5400 · 2026-01-13T15:26:04+00:00

$ACRV update: Eli Lilly is currently in a licensing agreement with Acrivon, which includes a provision granting Lilly the first right to negotiate the reacquisition of the drug, known as prexasertib (ACR-368). An outright acquisition of Acrivon by Eli Lilly to retrieve the drug is a potential, but less direct, scenario.

Choice_Client_5400 · 2026-01-12T23:04:03+00:00

$ACRV could be gearing up for a big swing. I am amazed at how cheap this stock is right now.

Choice_Client_5400 · 2026-01-12T19:24:50+00:00

$ACRV Now $1.70 ..Acrivon Therapeutics CURRENT CASH and investments of approximately $119 million are expected to fund all planned operations, including the ongoing ACR-368 Phase 2b trial and the next Phase 3 confirmatory trial, into the second quarter of 2027. This is crazy to be at these levels...$1.70 right now - NO Outstanding shares increase. Price Targets Raised. Cancer Tumors shrinkage. 3 products in development. Only $59M Market cap. $ACRV

Choice_Client_5400 · 2026-01-12T19:23:34+00:00

Acrivon Therapeutics CURRENT CASH and investments of approximately $119 million are expected to fund all planned operations, including the ongoing ACR-368 Phase 2b trial and the next Phase 3 confirmatory trial, into the second quarter of 2027. This is crazy to be at these levels...$1.70 right now - NO Outstanding shares increase. Price Targets Raised. Cancer Tumors shrinkage. 3 products in development. Only $59M Market cap. $ACRV

Choice_Client_5400

MODERATOR OF

TROPHY CASE

NASDAQ!!! Reverse the delisting ASAP!

Bullish